The Multiple Sclerosis Therapeutics Market size was estimated to be US$ 29.84 billion in 2023 and is expected to reach US$ 53.77 billion by 2031; it is estimated to record a CAGR of 6.8% till 2031. Development of novel therapies for treatment of multiple sclerosis, rise in R&D activities for development of drugs, and increasing cases of multiple sclerosis are likely to remain key Multiple Sclerosis Therapeutics Market trends.
The companies are focusing on development of various therapies for treatment of multiple sclerosis. For instance, in Feb 2024, Roche Pharma India launched Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in India.
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves which causes communication problems between the brain and rest of the body. Immunosuppressants and immunomodulators along with physiotherapy is widely used to treat MS. The MS therapeutics have evolved over the last few years with development of high efficacy disease modifying therapies targeting various mechanisms including immuno suppression or immuno modulation and enhance immune cell sequestration. The emerging therapy for MS includes CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation.
According to World Health Organization (WHO), in 2023, over 1.8 million people globally suffer from multiple sclerosis. Further, according to the National Multiple Sclerosis Society, about 1 million people in 2021 were affected by multiple sclerosis in the US. According to the South African Medical Journal, the burden of multiple sclerosis in sub-Saharan Africa is increasing, with approximately 6.1% in 2021. As of 2021, seven in 10,000 people—or 684 people—were reported to have multiple sclerosis in the UAE, with the average age of diagnosis being 28. Increase in prevalence of multiple sclerosis globally is fueling the growth of the multiple sclerosis therapeutics market.
Rise in funding is driving extensive multiple sclerosis research across the world to identify new treatments for the disease. For instance, in February 2023, researchers from the University of Tasmania’s Menzies Institute for Medical Research received research grant awarded by MS Australia in the funding round of multiple sclerosis research. They received US$ 818,966 for their MS research. In December 2023, the European Union is funding the international research consortium BEHIND-MS as part of its HORIZON Europe programme, which aims to identify specific biomarkers and to develop targeted therapies. The consortium, led by the German Cancer Research Center, will receive US$ 7.57 million (7.1 million euros) over a period of five years.
Key segments that contributed to the derivation of the Multiple Sclerosis Therapeutics Market analysis are type and application.
The geographic scope of the Multiple Sclerosis Therapeutics Market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
North America has dominated the Multiple Sclerosis Therapeutics Market. In North America, the US holds the significant share of the multiple sclerosis therapeutics market. The growth of the market in the country is primarily driven by vast number of R&D activities, financial aids by governments, other private, and non-private organizations for research, collaborations within pharmaceuticals and technology companies for development of products, and increasing prevalence of multiple sclerosis in the country. Additionally, increasing awareness regarding the multiple sclerosis treatment outcomes is expected to boost the adoption and acceptance of the products during the forecast period. Furthermore, the implementation of regulatory policies for approval of treatment of multiple sclerosis is likely to offer significant opportunity for the growth of the market during the forecast period. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Multiple Sclerosis Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Multiple Sclerosis Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 31.87 Billion |
| Market Size by 2031 | US$ 53.77 Billion |
| Global CAGR (2025 - 2031) | 6.8% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Multiple Sclerosis Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Multiple Sclerosis Therapeutics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Multiple Sclerosis Therapeutics Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for multiple sclerosis therapeutics and strategies:
The “Multiple Sclerosis Therapeutics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas: